Skip to main content

Mitomycin C plus cisplatin for systemic treatment of recurrent BRCA1-associated ovarian cancer


Background Previous studies on neoadjuvant therapy for BRCA1-driven ovarian cancer (OC) demonstrated higher efficacy of mitomycin C plus cisplatin combination as compared to standard drug schemes. These data call for evaluation of the utility of this regimen for the treatment of recurrent BRCA1-associated OC. Methods The study included 12 BRCA1 germ-line mutation carriers, whose disease relapsed after one (n = 4) or two (n = 8) lines of chemotherapy. The patients received cisplatin 100 mg/m2 and mitomycin C 10 mg/m2, given every four weeks, for 6 (n = 10), 8 (n = 1) or 5 (n = 1) cycles. Retrospective data on conventional treatment of OC relapses in BRCA1 heterozygotes (n = 47) served as a control. Results Grade 3–4 toxicities were observed in 4/12 (33%) cases. There were 6 complete responses (CR), 4 partial responses (PR) and 2 instances of stable disease (SD). Comparison of patients receiving mitomycin C plus cisplatin (n = 4) or conventional therapy (n = 44) at first relapse demonstrated marginal improvement of the progression-free survival (PFS) (16.6 months vs. 10.2 months, P = .067). Use of mitomycin C plus cisplatin (n = 8) for the treatment of second relapse resulted in significant prolongation of PFS as compared to standard regimens (n = 31) (14.8 months vs. 4.8 months, P = .002). Conclusions Mitomycin C plus cisplatin shows promising activity in recurrent BRCA1-driven ovarian cancer.

This is a preview of subscription content, access via your institution.

Fig. 1


  1. 1.

    Matulonis UA, Sood AK, Fallowfield L et al (2016) Ovarian cancer. Nat Rev Dis Primers 2:16061.

    Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Matulonis UA (2018) Management of newly diagnosed or recurrent ovarian cancer. Clin Adv Hematol Oncol 16(6):426–437

    PubMed  Google Scholar 

  3. 3.

    Lheureux S, Braunstein M, Oza AM (2019) Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin 69(4):280–304.

    Article  PubMed  Google Scholar 

  4. 4.

    Lheureux S, Gourley C, Vergote I et al (2019) Epithelial ovarian cancer. Lancet 393(10177):1240–1253.

    Article  PubMed  Google Scholar 

  5. 5.

    Marchetti C, De Leo R, Musella A et al (2018) BRCA mutation status to personalize management of recurrent ovarian cancer: A multicenter study. Ann Surg Oncol 25(12):3701–3708.

    Article  PubMed  Google Scholar 

  6. 6.

    Gorodnova T, Sokolenko A, Ni V et al (2019) BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy. Int J Gynecol Cancer 29(4):779–786.

    Article  PubMed  Google Scholar 

  7. 7.

    Gorodnova TV, Kotiv KB, Ivantsov AO et al (2018) Efficacy of neoadjuvant therapy with cisplatin plus mitomycin C in BRCA1-mutated ovarian cancer. Int J Gynecol Cancer 28(8):1498–1506.

    Article  PubMed  Google Scholar 

  8. 8.

    Safra T, Rogowski O, Muggia FM (2014) The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer. Int J Gynecol Cancer 24(3):488–495.

    Article  PubMed  Google Scholar 

  9. 9.

    Bookman MA, Tyczynski JE, Espirito JL et al (2017) Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer. Gynecol Oncol 146(1):58–63.

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Moiseyenko VM, Chubenko VA, Moiseyenko FV et al (2014) Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation. Med Oncol 31(10):199.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    NCCN clinical practice guidelines in oncology, Version 1.2020, ovarian cancer. Accessed 1 Apr 2020

  12. 12.

    Lindemann K, Gao B, Mapagu C et al (2018) Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. Gynecol Oncol 150(2):239–246.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Alsop K, Fereday S, Meldrum C et al (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30(21):2654–2663.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Sokolenko AP, Bizin IV, Preobrazhenskaya EV et al (2020) Molecular profiles of BRCA1-associated ovarian cancer treated by platinum-based therapy: Analysis of primary, residual and relapsed tumors. Int J Cancer 146(7):1879–1888.

    CAS  Article  PubMed  Google Scholar 

Download references


We are cordially thankful to Ms. Sophie Leonard for the editing of this manuscript.


This work has been supported by the Russian Science Foundation [grant number 19-75-10062].

Author information




Conceptualization: Tatyana V. Gorodnova, Evgeny N. Imyanitov.

Methodology: Tatyana V. Gorodnova, Anna P. Sokolenko, Evgeny N. Imyanitov.

Formal analysis and investigation: Tatiana V. Gorodnova, Sergey V. Kondratiev, Khristina B. Kotiv, Alexey M. Belyaev, Igor. V. Berlev.

Writing – original draft preparation: Anna P. Sokolenko, Evgeny N. Imyanitov.

Writing – review and editing: all authors.

Funding acquisition: Khristina B. Kotiv.

Corresponding author

Correspondence to Anna P. Sokolenko.

Ethics declarations

Conflict of interest

Tatyana V. Gorodnova, Anna P. Sokolenko, Sergey V. Kondratiev, Khristina B. Kotiv, Alexey M. Belyaev, Igor V. Berlev, and Evgeny N. Imyanitov declare that they have no conflicts of interest.

Ethical approval

The study was approved by the local Ethics Committee. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent

All patients provided written informed consent.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material


(PDF 150 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Gorodnova, T.V., Sokolenko, A.P., Kondratiev, S.V. et al. Mitomycin C plus cisplatin for systemic treatment of recurrent BRCA1-associated ovarian cancer. Invest New Drugs 38, 1872–1878 (2020).

Download citation


  • BRCA1 mutation
  • Mitomycin C plus cisplatin
  • Ovarian cancer
  • Recurrence